Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 Dabestani, 2016, Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study, World J Urol, 34, 1081, 10.1007/s00345-016-1773-y Choueiri, 2021, Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 384, 829, 10.1056/NEJMoa2026982 Motzer, 2021, Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma, N Engl J Med, 384, 1289, 10.1056/NEJMoa2035716 Rini, 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1116, 10.1056/NEJMoa1816714 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Dabestani, 2014, Local treatments for metastases of renal cell carcinoma: a systematic review, Lancet Oncol, 15, e549, 10.1016/S1470-2045(14)70235-9 Ouzaid, 2019, Surgical metastasectomy in renal cell carcinoma: a systematic review, Eur Urol Oncol, 2, 141, 10.1016/j.euo.2018.08.028 Dabestani, 2019, Intensive imaging-based follow-up of surgically treated localised renal cell carcinoma does not improve post-recurrence survival: results from a European multicentre database (RECUR), Eur Urol, 75, 261, 10.1016/j.eururo.2018.10.007 Dabestani, 2019, Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.), Scand J Urol, 53, 14, 10.1080/21681805.2019.1588919 Dabestani, 2019, Long-term outcomes of follow-up for initially localised clear cell renal cell carcinoma: RECUR database analysis, Eur Urol Focus, 5, 857, 10.1016/j.euf.2018.02.010 Leibovich, 2003, Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials, Cancer, 97, 1663, 10.1002/cncr.11234 Rosiello, 2022, Head-to-head comparison of all the prognostic models recommended by the European Association of Urology guidelines to predict oncologic outcomes in patients with renal cell carcinoma, Urol Oncol, 40, 271.e19, 10.1016/j.urolonc.2021.12.010 Usher-Smith, 2022, Risk models for recurrence and survival after kidney cancer: a systematic review, BJU Int, 130, 562, 10.1111/bju.15673 Ljungberg, 2019, European Association of Urology guidelines on renal cell carcinoma: the 2019 update, Eur Urol, 75, 799, 10.1016/j.eururo.2019.02.011 Bedke, 2022, 2021 Updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma, Eur Urol, 81, 134, 10.1016/j.eururo.2021.11.022 Motzer, 2020, NCCN guidelines insights: kidney cancer, version 1.2021, J Natl Compr Canc Netw, 18, 1160, 10.6004/jnccn.2020.0043 Escudier, 2019, Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 30, 706, 10.1093/annonc/mdz056 Hsieh, 2021, The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: a systematic review and meta-analysis, Urol Oncol, 39, 422, 10.1016/j.urolonc.2021.02.026 Zelefsky, 2012, Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma, Int J Radiat Oncol Biol Phys, 82, 1744, 10.1016/j.ijrobp.2011.02.040 Zerbi, 2008, Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection?, Ann Surg Oncol, 15, 1161, 10.1245/s10434-007-9782-0 Dragomir, 2020, Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: the Canadian Kidney Cancer information system experience, Urol Oncol, 38, 799.e1, 10.1016/j.urolonc.2020.07.021 Eggener, 2008, Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma, J Urol, 180, 873, 10.1016/j.juro.2008.05.006 Fuchs, 2005, Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment, Clin Orthop Relat Res, 431, 187, 10.1097/01.blo.0000149820.65137.b4 Sun, 2018, Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy, Eur J Surg Oncol, 44, 1439, 10.1016/j.ejso.2018.05.026 Li, 2018, The impact of local intervention combined with targeted therapy on metastatic renal cell carcinoma, Anticancer Res, 38, 5339, 10.21873/anticanres.12861 Tornberg, 2018, Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era, Scand J Urol, 52, 419, 10.1080/21681805.2018.1553893 Psutka, 2018, Role of metastasis-directed treatment in kidney cancer, Cancer, 124, 3641, 10.1002/cncr.31341 Procopio, 2019, Sorafenib versus observation following radical metastasectomy for clear-cell renal cell carcinoma: results from the phase 2 randomized open-label RESORT study, Eur Urol Oncol, 2, 699, 10.1016/j.euo.2019.08.011 Takagi, 2020, Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era, Urol Oncol, 38, 515, 10.1016/j.urolonc.2020.02.003 Verbiest, 2018, Molecular subtypes of clear-cell renal cell carcinoma are prognostic for outcome after complete metastasectomy, Eur Urol, 74, 474, 10.1016/j.eururo.2018.01.042 Liu, 2021, Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy, World J Urol, 39, 4183, 10.1007/s00345-021-03742-1 Stenman, 2018, Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005–2014, Radiother Oncol, 127, 501, 10.1016/j.radonc.2018.04.028 Siva, 2022, Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma—the RAPPORT trial, Eur Urol, 81, 364, 10.1016/j.eururo.2021.12.006 Kalra, 2017, Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era, Clin Genitourin Cancer, 15, 363, 10.1016/j.clgc.2017.01.010 Ruatta, 2019, Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre, Eur J Cancer, 107, 79, 10.1016/j.ejca.2018.10.023 Itano, 2000, Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy, J Urol, 164, 322, 10.1016/S0022-5347(05)67350-8 Amano, 2010, Contralateral metachronous tumor occurrence is more frequently associated with distant metastases or postoperative intrarenal recurrence in renal cell carcinoma patients, Int J Urol, 17, 615, 10.1111/j.1442-2042.2010.02541.x Bedke, 2021, The 2021 updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care, Eur Urol, 80, 393, 10.1016/j.eururo.2021.04.042